Brevan Howard Capital Management LP Buys 139,109 Shares of Pfizer Inc. (NYSE:PFE)

Brevan Howard Capital Management LP boosted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 167.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 222,421 shares of the biopharmaceutical company's stock after purchasing an additional 139,109 shares during the period. Brevan Howard Capital Management LP's holdings in Pfizer were worth $5,901,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. PSI Advisors LLC boosted its holdings in shares of Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after buying an additional 385 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its position in shares of Pfizer by 1.0% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock valued at $1,027,000 after acquiring an additional 391 shares during the period. D Orazio & Associates Inc. increased its holdings in shares of Pfizer by 5.5% in the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock worth $200,000 after purchasing an additional 391 shares during the period. Lipe & Dalton raised its holdings in shares of Pfizer by 17.7% in the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after acquiring an additional 400 shares in the last quarter. Finally, Oliver Luxxe Assets LLC grew its holdings in shares of Pfizer by 2.2% during the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock worth $499,000 after purchasing an additional 401 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Down 4.0 %

Shares of PFE stock traded down $0.95 during trading hours on Tuesday, hitting $22.92. 60,727,463 shares of the company's stock traded hands, compared to its average volume of 40,495,415. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $129.97 billion, a price-to-earnings ratio of 16.25, a PEG ratio of 0.64 and a beta of 0.58. The stock's fifty day simple moving average is $24.22 and its two-hundred day simple moving average is $25.67.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. During the same period last year, the business earned $0.82 EPS. Pfizer's revenue was down 7.8% compared to the same quarter last year. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.51%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.06% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on PFE. The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective on the stock. Finally, Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.